Blog

Giulio Francolini: QoL data from DART trial

Giulio Francolini/urotoday.com

May 4, 2025, 12:33

Giulio Francolini: QoL data from DART trial

Giulio Francolini, Radiation Oncologist at Careggi University Hospital, shared a post on X:

“QoL data from DART trial (SBRT+/- darolutamide in oligorec. pCa).

Global health and most QoL subdomains remained stable in both arms over the 24-week period.

More fatigue and hormonal treatment-related symptoms were observed in the SBRT and DARO arm, ESTRO.”

The post presents updated findings from the DART trial, indicating stable quality of life across both study arms over 24 weeks.

However, patients receiving both SBRT and darolutamide experienced increased fatigue and hormonal symptoms.

Stay tuned to OncoDaily for continued coverage and updates from ESTRO25.

cancer Careggi University Hospital darolutamide DART trial ESTRO fight against cancer Giulio Francolini Global fight against cancer global health OncoDaily Oncology QoL data Radiation Oncologist SBRT

Uhm Jung-hwa: Korea’s Iconic ‘Madonna’ and Her Triumphant Battle Against Thyroid Cancer

Vincent Rajkumar: A Historic Day for High Risk Smoldering Myeloma

Dr. Anastasia Constantinidou Nominated for Madame Figaro Woman of the Year 2025

Lisa A. Lacasse Welcomed Shane Jacobson as the New CEO of the ACS and the ACS CAN

ASCO and Community Oncology Alliance Have Released the Updated Oncology Medical Home Standards